Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: To know whether the production of OXA-48 carbapenemase exerts an independent impact on the outcome of Klebsiella pneumoniae infection, once adjusted by clinical syndrome and baseline risk factors.
METHODS: We performed a case-cohort study including 117 infectious episodes due to OXA-48-producing K. pneumoniae (OXA-48-Kp) and 117 episodes due to non-OXA-48-producing strains (non-OXA-48-Kp). Both groups were matched (1:1 ratio) by clinical syndrome (source of infection, preceding invasive procedures and indwelling devices, and associated bacteremia) and hospitalization ward at infection onset. Multivariate Cox regression was used to investigate the association between OXA-48-Kp infection and clinical cure by day 14 (primary outcome) and 30-day all-cause mortality (secondary outcome).
RESULTS: Both study groups were well balanced regarding underlying conditions and comorbidity burden. Sepsis or septic shock were more frequent in OXA-48-Kp cases than non-OXA-48-Kp controls (41 [35.0%] vs. 17 [14.5%]; P-value < 0.0001). Clinical cure by day 14 was less commonly achieved in OXA-48-Kp cases (49 [41.9%] vs. 95 [81.2%]; P-value < 0.001), whereas 30-day all-cause mortality was higher (33 [28.2%] vs. 18 [15.4%]; P-value = 0.018). Multivariate analysis confirmed that OXA-48-Kp infection was independently associated with the lack of 14-day clinical cure (adjusted hazard ratio [aHR]: 0.45; 95% confidential interval [95%CI]: 0.29-0.70; P-value < 0.0001). A non-significant association was observed for 30-day all-cause mortality (aHR: 1.65; 95%CI: 0.92-2.94; P-value = 0.093).
CONCLUSION: Our matched analysis suggests that the production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in K. pneumoniae infection as compared to episodes due to non-carbapenemase-producing strains.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 42(2023), 12 vom: 07. Dez., Seite 1485-1497 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Corbella, Laura [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10096-023-04675-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM363814361 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM363814361 | ||
003 | DE-627 | ||
005 | 20240214232900.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10096-023-04675-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1293.xml |
035 | |a (DE-627)NLM363814361 | ||
035 | |a (NLM)37889370 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Corbella, Laura |e verfasserin |4 aut | |
245 | 1 | 0 | |a Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.02.2024 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a PURPOSE: To know whether the production of OXA-48 carbapenemase exerts an independent impact on the outcome of Klebsiella pneumoniae infection, once adjusted by clinical syndrome and baseline risk factors | ||
520 | |a METHODS: We performed a case-cohort study including 117 infectious episodes due to OXA-48-producing K. pneumoniae (OXA-48-Kp) and 117 episodes due to non-OXA-48-producing strains (non-OXA-48-Kp). Both groups were matched (1:1 ratio) by clinical syndrome (source of infection, preceding invasive procedures and indwelling devices, and associated bacteremia) and hospitalization ward at infection onset. Multivariate Cox regression was used to investigate the association between OXA-48-Kp infection and clinical cure by day 14 (primary outcome) and 30-day all-cause mortality (secondary outcome) | ||
520 | |a RESULTS: Both study groups were well balanced regarding underlying conditions and comorbidity burden. Sepsis or septic shock were more frequent in OXA-48-Kp cases than non-OXA-48-Kp controls (41 [35.0%] vs. 17 [14.5%]; P-value < 0.0001). Clinical cure by day 14 was less commonly achieved in OXA-48-Kp cases (49 [41.9%] vs. 95 [81.2%]; P-value < 0.001), whereas 30-day all-cause mortality was higher (33 [28.2%] vs. 18 [15.4%]; P-value = 0.018). Multivariate analysis confirmed that OXA-48-Kp infection was independently associated with the lack of 14-day clinical cure (adjusted hazard ratio [aHR]: 0.45; 95% confidential interval [95%CI]: 0.29-0.70; P-value < 0.0001). A non-significant association was observed for 30-day all-cause mortality (aHR: 1.65; 95%CI: 0.92-2.94; P-value = 0.093) | ||
520 | |a CONCLUSION: Our matched analysis suggests that the production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in K. pneumoniae infection as compared to episodes due to non-carbapenemase-producing strains | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Klebsiella pneumoniae | |
650 | 4 | |a OXA-48 carbapenemase | |
650 | 4 | |a Outcomes | |
650 | 4 | |a Risk factor | |
650 | 4 | |a Virulence | |
650 | 7 | |a carbapenemase |2 NLM | |
650 | 7 | |a EC 3.5.2.6 |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a beta-Lactamases |2 NLM | |
650 | 7 | |a EC 3.5.2.6 |2 NLM | |
650 | 7 | |a Bacterial Proteins |2 NLM | |
700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
700 | 1 | |a Ruiz-Ruigómez, María |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez-Goncer, Isabel |e verfasserin |4 aut | |
700 | 1 | |a Silva, José Tiago |e verfasserin |4 aut | |
700 | 1 | |a Hernández-Jiménez, Pilar |e verfasserin |4 aut | |
700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Lizasoain, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Villa, Jennifer |e verfasserin |4 aut | |
700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
700 | 1 | |a San-Juan, Rafael |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 42(2023), 12 vom: 07. Dez., Seite 1485-1497 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2023 |g number:12 |g day:07 |g month:12 |g pages:1485-1497 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-023-04675-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2023 |e 12 |b 07 |c 12 |h 1485-1497 |